nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS1—esophageal cancer	0.263	0.636	CbGaD
Mesalazine—MPO—Carboplatin—esophageal cancer	0.159	0.465	CbGbCtD
Mesalazine—PTGS2—esophageal cancer	0.15	0.364	CbGaD
Mesalazine—MPO—Cisplatin—esophageal cancer	0.136	0.398	CbGbCtD
Mesalazine—PTGS2—Cisplatin—esophageal cancer	0.0468	0.137	CbGbCtD
Mesalazine—CHUK—epithelium—esophageal cancer	0.00245	0.0747	CbGeAlD
Mesalazine—CHUK—digestive system—esophageal cancer	0.00186	0.0568	CbGeAlD
Mesalazine—IKBKB—bronchus—esophageal cancer	0.00164	0.05	CbGeAlD
Mesalazine—IKBKB—smooth muscle tissue—esophageal cancer	0.0016	0.0489	CbGeAlD
Mesalazine—CHUK—lung—esophageal cancer	0.00155	0.0475	CbGeAlD
Mesalazine—PPARG—neck—esophageal cancer	0.00152	0.0464	CbGeAlD
Mesalazine—ALOX5—bronchus—esophageal cancer	0.00136	0.0414	CbGeAlD
Mesalazine—ALOX5—smooth muscle tissue—esophageal cancer	0.00133	0.0405	CbGeAlD
Mesalazine—IKBKB—digestive system—esophageal cancer	0.00127	0.0386	CbGeAlD
Mesalazine—MPO—epithelium—esophageal cancer	0.00117	0.0356	CbGeAlD
Mesalazine—CHUK—lymph node—esophageal cancer	0.00106	0.0325	CbGeAlD
Mesalazine—IKBKB—lung—esophageal cancer	0.00106	0.0323	CbGeAlD
Mesalazine—ALOX5—digestive system—esophageal cancer	0.00105	0.032	CbGeAlD
Mesalazine—PPARG—epithelium—esophageal cancer	0.00103	0.0316	CbGeAlD
Mesalazine—PPARG—smooth muscle tissue—esophageal cancer	0.000997	0.0304	CbGeAlD
Mesalazine—MPO—digestive system—esophageal cancer	0.000887	0.0271	CbGeAlD
Mesalazine—ALOX5—lung—esophageal cancer	0.000876	0.0267	CbGeAlD
Mesalazine—PPARG—digestive system—esophageal cancer	0.000787	0.024	CbGeAlD
Mesalazine—MPO—lung—esophageal cancer	0.000741	0.0226	CbGeAlD
Mesalazine—IKBKB—lymph node—esophageal cancer	0.000723	0.0221	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS1—esophageal cancer	0.000664	0.185	CrCbGaD
Mesalazine—PPARG—lung—esophageal cancer	0.000657	0.0201	CbGeAlD
Mesalazine—ALOX5—lymph node—esophageal cancer	0.000599	0.0183	CbGeAlD
Mesalazine—PTGS1—epithelium—esophageal cancer	0.000553	0.0169	CbGeAlD
Mesalazine—PTGS1—smooth muscle tissue—esophageal cancer	0.000533	0.0163	CbGeAlD
Mesalazine—PTGS2—epithelium—esophageal cancer	0.000529	0.0161	CbGeAlD
Mesalazine—PTGS2—bronchus—esophageal cancer	0.000521	0.0159	CbGeAlD
Mesalazine—PTGS2—smooth muscle tissue—esophageal cancer	0.000509	0.0156	CbGeAlD
Mesalazine—MPO—lymph node—esophageal cancer	0.000507	0.0155	CbGeAlD
Mesalazine—PTGS1—trachea—esophageal cancer	0.000489	0.0149	CbGeAlD
Mesalazine—PTGS2—trachea—esophageal cancer	0.000468	0.0143	CbGeAlD
Mesalazine—Olsalazine—PTGS1—esophageal cancer	0.000455	0.127	CrCbGaD
Mesalazine—PPARG—lymph node—esophageal cancer	0.00045	0.0137	CbGeAlD
Mesalazine—Aminosalicylic Acid—PTGS1—esophageal cancer	0.000428	0.119	CrCbGaD
Mesalazine—Diflunisal—PTGS1—esophageal cancer	0.000428	0.119	CrCbGaD
Mesalazine—PTGS1—digestive system—esophageal cancer	0.000421	0.0129	CbGeAlD
Mesalazine—PTGS2—digestive system—esophageal cancer	0.000402	0.0123	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—esophageal cancer	0.000379	0.106	CrCbGaD
Mesalazine—PTGS1—lung—esophageal cancer	0.000351	0.0107	CbGeAlD
Mesalazine—PTGS2—lung—esophageal cancer	0.000336	0.0103	CbGeAlD
Mesalazine—Olsalazine—PTGS2—esophageal cancer	0.00026	0.0724	CrCbGaD
Mesalazine—Diflunisal—PTGS2—esophageal cancer	0.000244	0.0681	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—esophageal cancer	0.000244	0.0681	CrCbGaD
Mesalazine—PTGS1—lymph node—esophageal cancer	0.00024	0.00734	CbGeAlD
Mesalazine—Salicylic acid—PTGS1—esophageal cancer	0.000238	0.0662	CrCbGaD
Mesalazine—PTGS2—lymph node—esophageal cancer	0.00023	0.00702	CbGeAlD
Mesalazine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000176	0.00177	CcSEcCtD
Mesalazine—Eye disorder—Cisplatin—esophageal cancer	0.000175	0.00176	CcSEcCtD
Mesalazine—Tinnitus—Cisplatin—esophageal cancer	0.000175	0.00175	CcSEcCtD
Mesalazine—Lymphadenopathy—Methotrexate—esophageal cancer	0.000175	0.00175	CcSEcCtD
Mesalazine—Cardiac disorder—Cisplatin—esophageal cancer	0.000174	0.00174	CcSEcCtD
Mesalazine—Abdominal distension—Capecitabine—esophageal cancer	0.000174	0.00174	CcSEcCtD
Mesalazine—Dysphagia—Capecitabine—esophageal cancer	0.000173	0.00173	CcSEcCtD
Mesalazine—Influenza—Capecitabine—esophageal cancer	0.000173	0.00173	CcSEcCtD
Mesalazine—Asthma—Capecitabine—esophageal cancer	0.000173	0.00173	CcSEcCtD
Mesalazine—Bronchospasm—Capecitabine—esophageal cancer	0.00017	0.0017	CcSEcCtD
Mesalazine—Photosensitivity—Methotrexate—esophageal cancer	0.00017	0.0017	CcSEcCtD
Mesalazine—Immune system disorder—Cisplatin—esophageal cancer	0.00017	0.0017	CcSEcCtD
Mesalazine—Mediastinal disorder—Cisplatin—esophageal cancer	0.000169	0.00169	CcSEcCtD
Mesalazine—Angina pectoris—Capecitabine—esophageal cancer	0.000168	0.00169	CcSEcCtD
Mesalazine—Bronchitis—Capecitabine—esophageal cancer	0.000166	0.00166	CcSEcCtD
Mesalazine—Alopecia—Cisplatin—esophageal cancer	0.000166	0.00166	CcSEcCtD
Mesalazine—Abdominal discomfort—Capecitabine—esophageal cancer	0.000166	0.00166	CcSEcCtD
Mesalazine—Hepatic failure—Methotrexate—esophageal cancer	0.000166	0.00166	CcSEcCtD
Mesalazine—Pancytopenia—Capecitabine—esophageal cancer	0.000164	0.00164	CcSEcCtD
Mesalazine—Erythema—Cisplatin—esophageal cancer	0.000163	0.00164	CcSEcCtD
Mesalazine—Dysuria—Capecitabine—esophageal cancer	0.000162	0.00162	CcSEcCtD
Mesalazine—Neutropenia—Capecitabine—esophageal cancer	0.000162	0.00162	CcSEcCtD
Mesalazine—Renal failure acute—Methotrexate—esophageal cancer	0.000161	0.00161	CcSEcCtD
Mesalazine—Flatulence—Cisplatin—esophageal cancer	0.000161	0.00161	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000161	0.00161	CcSEcCtD
Mesalazine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000158	0.00158	CcSEcCtD
Mesalazine—Weight increased—Capecitabine—esophageal cancer	0.000157	0.00158	CcSEcCtD
Mesalazine—Muscle spasms—Cisplatin—esophageal cancer	0.000157	0.00157	CcSEcCtD
Mesalazine—Weight decreased—Capecitabine—esophageal cancer	0.000156	0.00157	CcSEcCtD
Mesalazine—Pneumonia—Capecitabine—esophageal cancer	0.000155	0.00155	CcSEcCtD
Mesalazine—Infestation NOS—Capecitabine—esophageal cancer	0.000154	0.00154	CcSEcCtD
Mesalazine—Infestation—Capecitabine—esophageal cancer	0.000154	0.00154	CcSEcCtD
Mesalazine—Vision blurred—Cisplatin—esophageal cancer	0.000154	0.00154	CcSEcCtD
Mesalazine—Depression—Capecitabine—esophageal cancer	0.000154	0.00154	CcSEcCtD
Mesalazine—Tremor—Cisplatin—esophageal cancer	0.000153	0.00153	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000153	0.00153	CcSEcCtD
Mesalazine—Lethargy—Methotrexate—esophageal cancer	0.000152	0.00152	CcSEcCtD
Mesalazine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000152	0.00152	CcSEcCtD
Mesalazine—Renal failure—Capecitabine—esophageal cancer	0.000152	0.00152	CcSEcCtD
Mesalazine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000151	0.00151	CcSEcCtD
Mesalazine—Anaemia—Cisplatin—esophageal cancer	0.000151	0.00151	CcSEcCtD
Mesalazine—Jaundice—Capecitabine—esophageal cancer	0.00015	0.0015	CcSEcCtD
Mesalazine—Stomatitis—Capecitabine—esophageal cancer	0.00015	0.0015	CcSEcCtD
Mesalazine—Urinary tract infection—Capecitabine—esophageal cancer	0.00015	0.0015	CcSEcCtD
Mesalazine—Conjunctivitis—Capecitabine—esophageal cancer	0.00015	0.0015	CcSEcCtD
Mesalazine—Osteoarthritis—Methotrexate—esophageal cancer	0.000149	0.00149	CcSEcCtD
Mesalazine—Malaise—Cisplatin—esophageal cancer	0.000147	0.00148	CcSEcCtD
Mesalazine—Haematuria—Capecitabine—esophageal cancer	0.000147	0.00147	CcSEcCtD
Mesalazine—Leukopenia—Cisplatin—esophageal cancer	0.000146	0.00146	CcSEcCtD
Mesalazine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000146	0.00146	CcSEcCtD
Mesalazine—Epistaxis—Capecitabine—esophageal cancer	0.000145	0.00146	CcSEcCtD
Mesalazine—Agranulocytosis—Capecitabine—esophageal cancer	0.000144	0.00144	CcSEcCtD
Mesalazine—Mood swings—Methotrexate—esophageal cancer	0.000141	0.00141	CcSEcCtD
Mesalazine—Myalgia—Cisplatin—esophageal cancer	0.000139	0.00139	CcSEcCtD
Mesalazine—Haemoglobin—Capecitabine—esophageal cancer	0.000139	0.00139	CcSEcCtD
Mesalazine—Rhinitis—Capecitabine—esophageal cancer	0.000139	0.00139	CcSEcCtD
Mesalazine—Anxiety—Cisplatin—esophageal cancer	0.000139	0.00139	CcSEcCtD
Mesalazine—Haemorrhage—Capecitabine—esophageal cancer	0.000138	0.00139	CcSEcCtD
Mesalazine—Hepatitis—Capecitabine—esophageal cancer	0.000138	0.00139	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000138	0.00138	CcSEcCtD
Mesalazine—Liver function test abnormal—Methotrexate—esophageal cancer	0.000137	0.00138	CcSEcCtD
Mesalazine—Discomfort—Cisplatin—esophageal cancer	0.000137	0.00138	CcSEcCtD
Mesalazine—Pharyngitis—Capecitabine—esophageal cancer	0.000137	0.00138	CcSEcCtD
Mesalazine—Urinary tract disorder—Capecitabine—esophageal cancer	0.000137	0.00137	CcSEcCtD
Mesalazine—Oedema peripheral—Capecitabine—esophageal cancer	0.000136	0.00136	CcSEcCtD
Mesalazine—Salicylic acid—PTGS2—esophageal cancer	0.000136	0.0379	CrCbGaD
Mesalazine—Connective tissue disorder—Capecitabine—esophageal cancer	0.000136	0.00136	CcSEcCtD
Mesalazine—Urethral disorder—Capecitabine—esophageal cancer	0.000136	0.00136	CcSEcCtD
Mesalazine—Breast disorder—Methotrexate—esophageal cancer	0.000135	0.00135	CcSEcCtD
Mesalazine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000133	0.00134	CcSEcCtD
Mesalazine—Oedema—Cisplatin—esophageal cancer	0.000133	0.00134	CcSEcCtD
Mesalazine—Infection—Cisplatin—esophageal cancer	0.000132	0.00133	CcSEcCtD
Mesalazine—Erythema multiforme—Capecitabine—esophageal cancer	0.000131	0.00131	CcSEcCtD
Mesalazine—Nervous system disorder—Cisplatin—esophageal cancer	0.000131	0.00131	CcSEcCtD
Mesalazine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000131	0.00131	CcSEcCtD
Mesalazine—Tachycardia—Cisplatin—esophageal cancer	0.00013	0.0013	CcSEcCtD
Mesalazine—Skin disorder—Cisplatin—esophageal cancer	0.00013	0.0013	CcSEcCtD
Mesalazine—Eye disorder—Capecitabine—esophageal cancer	0.000129	0.00129	CcSEcCtD
Mesalazine—Tinnitus—Capecitabine—esophageal cancer	0.000129	0.00129	CcSEcCtD
Mesalazine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000129	0.00129	CcSEcCtD
Mesalazine—Asthma—Methotrexate—esophageal cancer	0.000129	0.00129	CcSEcCtD
Mesalazine—Cardiac disorder—Capecitabine—esophageal cancer	0.000128	0.00129	CcSEcCtD
Mesalazine—Eosinophilia—Methotrexate—esophageal cancer	0.000127	0.00128	CcSEcCtD
Mesalazine—Anorexia—Cisplatin—esophageal cancer	0.000127	0.00127	CcSEcCtD
Mesalazine—Pancreatitis—Methotrexate—esophageal cancer	0.000126	0.00126	CcSEcCtD
Mesalazine—Angiopathy—Capecitabine—esophageal cancer	0.000126	0.00126	CcSEcCtD
Mesalazine—Immune system disorder—Capecitabine—esophageal cancer	0.000125	0.00125	CcSEcCtD
Mesalazine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000125	0.00125	CcSEcCtD
Mesalazine—Hypotension—Cisplatin—esophageal cancer	0.000125	0.00125	CcSEcCtD
Mesalazine—Chills—Capecitabine—esophageal cancer	0.000124	0.00124	CcSEcCtD
Mesalazine—Abdominal discomfort—Methotrexate—esophageal cancer	0.000123	0.00124	CcSEcCtD
Mesalazine—Alopecia—Capecitabine—esophageal cancer	0.000122	0.00122	CcSEcCtD
Mesalazine—Pancytopenia—Methotrexate—esophageal cancer	0.000122	0.00122	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000121	0.00122	CcSEcCtD
Mesalazine—Mental disorder—Capecitabine—esophageal cancer	0.000121	0.00121	CcSEcCtD
Mesalazine—Erythema—Capecitabine—esophageal cancer	0.00012	0.00121	CcSEcCtD
Mesalazine—Neutropenia—Methotrexate—esophageal cancer	0.00012	0.0012	CcSEcCtD
Mesalazine—Dysuria—Methotrexate—esophageal cancer	0.00012	0.0012	CcSEcCtD
Mesalazine—Paraesthesia—Cisplatin—esophageal cancer	0.00012	0.0012	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00012	0.0012	CcSEcCtD
Mesalazine—Dyspnoea—Cisplatin—esophageal cancer	0.000119	0.00119	CcSEcCtD
Mesalazine—Flatulence—Capecitabine—esophageal cancer	0.000119	0.00119	CcSEcCtD
Mesalazine—Dysgeusia—Capecitabine—esophageal cancer	0.000118	0.00118	CcSEcCtD
Mesalazine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000117	0.00118	CcSEcCtD
Mesalazine—Back pain—Capecitabine—esophageal cancer	0.000117	0.00117	CcSEcCtD
Mesalazine—Decreased appetite—Cisplatin—esophageal cancer	0.000116	0.00116	CcSEcCtD
Mesalazine—Muscle spasms—Capecitabine—esophageal cancer	0.000116	0.00116	CcSEcCtD
Mesalazine—Salicylic acid—ABCB1—esophageal cancer	0.000116	0.0322	CrCbGaD
Mesalazine—Pneumonia—Methotrexate—esophageal cancer	0.000115	0.00116	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000115	0.00115	CcSEcCtD
Mesalazine—Infestation NOS—Methotrexate—esophageal cancer	0.000115	0.00115	CcSEcCtD
Mesalazine—Infestation—Methotrexate—esophageal cancer	0.000115	0.00115	CcSEcCtD
Mesalazine—Depression—Methotrexate—esophageal cancer	0.000114	0.00115	CcSEcCtD
Mesalazine—Pain—Cisplatin—esophageal cancer	0.000114	0.00114	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000114	0.00114	CcSEcCtD
Mesalazine—Vision blurred—Capecitabine—esophageal cancer	0.000114	0.00114	CcSEcCtD
Mesalazine—Tremor—Capecitabine—esophageal cancer	0.000113	0.00113	CcSEcCtD
Mesalazine—Renal failure—Methotrexate—esophageal cancer	0.000113	0.00113	CcSEcCtD
Mesalazine—Stomatitis—Methotrexate—esophageal cancer	0.000112	0.00112	CcSEcCtD
Mesalazine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000112	0.00112	CcSEcCtD
Mesalazine—Conjunctivitis—Methotrexate—esophageal cancer	0.000112	0.00112	CcSEcCtD
Mesalazine—Anaemia—Capecitabine—esophageal cancer	0.000111	0.00111	CcSEcCtD
Mesalazine—Sweating—Methotrexate—esophageal cancer	0.00011	0.0011	CcSEcCtD
Mesalazine—Feeling abnormal—Cisplatin—esophageal cancer	0.00011	0.0011	CcSEcCtD
Mesalazine—Haematuria—Methotrexate—esophageal cancer	0.000109	0.0011	CcSEcCtD
Mesalazine—Malaise—Capecitabine—esophageal cancer	0.000109	0.00109	CcSEcCtD
Mesalazine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000109	0.00109	CcSEcCtD
Mesalazine—Epistaxis—Methotrexate—esophageal cancer	0.000108	0.00108	CcSEcCtD
Mesalazine—Vertigo—Capecitabine—esophageal cancer	0.000108	0.00108	CcSEcCtD
Mesalazine—Syncope—Capecitabine—esophageal cancer	0.000108	0.00108	CcSEcCtD
Mesalazine—Leukopenia—Capecitabine—esophageal cancer	0.000108	0.00108	CcSEcCtD
Mesalazine—Agranulocytosis—Methotrexate—esophageal cancer	0.000107	0.00107	CcSEcCtD
Mesalazine—Palpitations—Capecitabine—esophageal cancer	0.000106	0.00107	CcSEcCtD
Mesalazine—Loss of consciousness—Capecitabine—esophageal cancer	0.000106	0.00106	CcSEcCtD
Mesalazine—Body temperature increased—Cisplatin—esophageal cancer	0.000105	0.00106	CcSEcCtD
Mesalazine—Cough—Capecitabine—esophageal cancer	0.000105	0.00105	CcSEcCtD
Mesalazine—Hypertension—Capecitabine—esophageal cancer	0.000104	0.00104	CcSEcCtD
Mesalazine—Haemoglobin—Methotrexate—esophageal cancer	0.000104	0.00104	CcSEcCtD
Mesalazine—Haemorrhage—Methotrexate—esophageal cancer	0.000103	0.00103	CcSEcCtD
Mesalazine—Hepatitis—Methotrexate—esophageal cancer	0.000103	0.00103	CcSEcCtD
Mesalazine—Arthralgia—Capecitabine—esophageal cancer	0.000103	0.00103	CcSEcCtD
Mesalazine—Chest pain—Capecitabine—esophageal cancer	0.000103	0.00103	CcSEcCtD
Mesalazine—Myalgia—Capecitabine—esophageal cancer	0.000103	0.00103	CcSEcCtD
Mesalazine—Pharyngitis—Methotrexate—esophageal cancer	0.000102	0.00102	CcSEcCtD
Mesalazine—Anxiety—Capecitabine—esophageal cancer	0.000102	0.00102	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000102	0.00102	CcSEcCtD
Mesalazine—Urinary tract disorder—Methotrexate—esophageal cancer	0.000102	0.00102	CcSEcCtD
Mesalazine—Discomfort—Capecitabine—esophageal cancer	0.000101	0.00101	CcSEcCtD
Mesalazine—Urethral disorder—Methotrexate—esophageal cancer	0.000101	0.00101	CcSEcCtD
Mesalazine—Dry mouth—Capecitabine—esophageal cancer	0.0001	0.001	CcSEcCtD
Mesalazine—Confusional state—Capecitabine—esophageal cancer	9.91e-05	0.000993	CcSEcCtD
Mesalazine—Oedema—Capecitabine—esophageal cancer	9.83e-05	0.000984	CcSEcCtD
Mesalazine—Hypersensitivity—Cisplatin—esophageal cancer	9.82e-05	0.000984	CcSEcCtD
Mesalazine—Infection—Capecitabine—esophageal cancer	9.77e-05	0.000978	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—esophageal cancer	9.74e-05	0.000975	CcSEcCtD
Mesalazine—Shock—Capecitabine—esophageal cancer	9.67e-05	0.000968	CcSEcCtD
Mesalazine—Nervous system disorder—Capecitabine—esophageal cancer	9.64e-05	0.000965	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—esophageal cancer	9.63e-05	0.000964	CcSEcCtD
Mesalazine—Thrombocytopenia—Capecitabine—esophageal cancer	9.62e-05	0.000964	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—esophageal cancer	9.6e-05	0.000962	CcSEcCtD
Mesalazine—Tachycardia—Capecitabine—esophageal cancer	9.59e-05	0.000961	CcSEcCtD
Mesalazine—Asthenia—Cisplatin—esophageal cancer	9.57e-05	0.000958	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—esophageal cancer	9.56e-05	0.000957	CcSEcCtD
Mesalazine—Skin disorder—Capecitabine—esophageal cancer	9.55e-05	0.000956	CcSEcCtD
Mesalazine—Hyperhidrosis—Capecitabine—esophageal cancer	9.5e-05	0.000952	CcSEcCtD
Mesalazine—Anorexia—Capecitabine—esophageal cancer	9.37e-05	0.000938	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—esophageal cancer	9.34e-05	0.000936	CcSEcCtD
Mesalazine—Immune system disorder—Methotrexate—esophageal cancer	9.3e-05	0.000932	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—esophageal cancer	9.28e-05	0.00093	CcSEcCtD
Mesalazine—Chills—Methotrexate—esophageal cancer	9.24e-05	0.000925	CcSEcCtD
Mesalazine—Hypotension—Capecitabine—esophageal cancer	9.19e-05	0.00092	CcSEcCtD
Mesalazine—Diarrhoea—Cisplatin—esophageal cancer	9.12e-05	0.000914	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—esophageal cancer	9.1e-05	0.000911	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—esophageal cancer	9.02e-05	0.000904	CcSEcCtD
Mesalazine—Erythema—Methotrexate—esophageal cancer	8.97e-05	0.000898	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	8.96e-05	0.000897	CcSEcCtD
Mesalazine—Insomnia—Capecitabine—esophageal cancer	8.89e-05	0.00089	CcSEcCtD
Mesalazine—Paraesthesia—Capecitabine—esophageal cancer	8.83e-05	0.000884	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—esophageal cancer	8.78e-05	0.000879	CcSEcCtD
Mesalazine—Dyspnoea—Capecitabine—esophageal cancer	8.76e-05	0.000878	CcSEcCtD
Mesalazine—Back pain—Methotrexate—esophageal cancer	8.67e-05	0.000868	CcSEcCtD
Mesalazine—Dyspepsia—Capecitabine—esophageal cancer	8.65e-05	0.000866	CcSEcCtD
Mesalazine—Decreased appetite—Capecitabine—esophageal cancer	8.55e-05	0.000856	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Capecitabine—esophageal cancer	8.49e-05	0.00085	CcSEcCtD
Mesalazine—Vomiting—Cisplatin—esophageal cancer	8.48e-05	0.000849	CcSEcCtD
Mesalazine—Fatigue—Capecitabine—esophageal cancer	8.47e-05	0.000849	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—esophageal cancer	8.45e-05	0.000846	CcSEcCtD
Mesalazine—Rash—Cisplatin—esophageal cancer	8.41e-05	0.000842	CcSEcCtD
Mesalazine—Constipation—Capecitabine—esophageal cancer	8.41e-05	0.000842	CcSEcCtD
Mesalazine—Pain—Capecitabine—esophageal cancer	8.41e-05	0.000842	CcSEcCtD
Mesalazine—Dermatitis—Cisplatin—esophageal cancer	8.4e-05	0.000841	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—esophageal cancer	8.32e-05	0.000833	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—esophageal cancer	8.29e-05	0.00083	CcSEcCtD
Mesalazine—Feeling abnormal—Capecitabine—esophageal cancer	8.1e-05	0.000811	CcSEcCtD
Mesalazine—Malaise—Methotrexate—esophageal cancer	8.09e-05	0.00081	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—esophageal cancer	8.06e-05	0.000807	CcSEcCtD
Mesalazine—Gastrointestinal pain—Capecitabine—esophageal cancer	8.04e-05	0.000805	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—esophageal cancer	8.03e-05	0.000804	CcSEcCtD
Mesalazine—Nausea—Cisplatin—esophageal cancer	7.92e-05	0.000793	CcSEcCtD
Mesalazine—Cough—Methotrexate—esophageal cancer	7.82e-05	0.000783	CcSEcCtD
Mesalazine—Urticaria—Capecitabine—esophageal cancer	7.81e-05	0.000782	CcSEcCtD
Mesalazine—Body temperature increased—Capecitabine—esophageal cancer	7.77e-05	0.000778	CcSEcCtD
Mesalazine—Abdominal pain—Capecitabine—esophageal cancer	7.77e-05	0.000778	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—esophageal cancer	7.63e-05	0.000764	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—esophageal cancer	7.63e-05	0.000764	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—esophageal cancer	7.63e-05	0.000764	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	7.58e-05	0.000759	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—esophageal cancer	7.54e-05	0.000755	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—esophageal cancer	7.38e-05	0.000739	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—esophageal cancer	7.32e-05	0.000733	CcSEcCtD
Mesalazine—Infection—Methotrexate—esophageal cancer	7.27e-05	0.000728	CcSEcCtD
Mesalazine—Hypersensitivity—Capecitabine—esophageal cancer	7.24e-05	0.000725	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—esophageal cancer	7.18e-05	0.000719	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—esophageal cancer	7.16e-05	0.000717	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—esophageal cancer	7.11e-05	0.000712	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—esophageal cancer	7.07e-05	0.000708	CcSEcCtD
Mesalazine—Asthenia—Capecitabine—esophageal cancer	7.05e-05	0.000706	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—esophageal cancer	6.98e-05	0.000698	CcSEcCtD
Mesalazine—Pruritus—Capecitabine—esophageal cancer	6.95e-05	0.000696	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—esophageal cancer	6.84e-05	0.000685	CcSEcCtD
Mesalazine—Diarrhoea—Capecitabine—esophageal cancer	6.73e-05	0.000673	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	6.67e-05	0.000668	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—esophageal cancer	6.62e-05	0.000663	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—esophageal cancer	6.57e-05	0.000658	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—esophageal cancer	6.52e-05	0.000653	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—esophageal cancer	6.51e-05	0.000651	CcSEcCtD
Mesalazine—Dizziness—Capecitabine—esophageal cancer	6.5e-05	0.000651	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—esophageal cancer	6.44e-05	0.000645	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—esophageal cancer	6.36e-05	0.000637	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—esophageal cancer	6.32e-05	0.000633	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—esophageal cancer	6.31e-05	0.000632	CcSEcCtD
Mesalazine—Pain—Methotrexate—esophageal cancer	6.26e-05	0.000627	CcSEcCtD
Mesalazine—Vomiting—Capecitabine—esophageal cancer	6.25e-05	0.000626	CcSEcCtD
Mesalazine—Rash—Capecitabine—esophageal cancer	6.2e-05	0.000621	CcSEcCtD
Mesalazine—Dermatitis—Capecitabine—esophageal cancer	6.19e-05	0.00062	CcSEcCtD
Mesalazine—Headache—Capecitabine—esophageal cancer	6.16e-05	0.000617	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—esophageal cancer	6.03e-05	0.000604	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—esophageal cancer	5.98e-05	0.000599	CcSEcCtD
Mesalazine—Nausea—Capecitabine—esophageal cancer	5.84e-05	0.000585	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—esophageal cancer	5.81e-05	0.000582	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—esophageal cancer	5.78e-05	0.000579	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—esophageal cancer	5.78e-05	0.000579	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—esophageal cancer	5.39e-05	0.00054	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—esophageal cancer	5.25e-05	0.000526	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—esophageal cancer	5.18e-05	0.000518	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—esophageal cancer	5.01e-05	0.000501	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—esophageal cancer	4.84e-05	0.000485	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—esophageal cancer	4.65e-05	0.000466	CcSEcCtD
Mesalazine—Rash—Methotrexate—esophageal cancer	4.61e-05	0.000462	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—esophageal cancer	4.61e-05	0.000462	CcSEcCtD
Mesalazine—Headache—Methotrexate—esophageal cancer	4.58e-05	0.000459	CcSEcCtD
Mesalazine—Nausea—Methotrexate—esophageal cancer	4.35e-05	0.000435	CcSEcCtD
Mesalazine—PTGS1—Metabolism—CYP26A1—esophageal cancer	2e-05	0.000183	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—TLR4—esophageal cancer	1.99e-05	0.000182	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.99e-05	0.000182	CbGpPWpGaD
Mesalazine—CHUK—Disease—FBXW7—esophageal cancer	1.97e-05	0.00018	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALOX15—esophageal cancer	1.95e-05	0.000178	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PLCE1—esophageal cancer	1.94e-05	0.000178	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ADH7—esophageal cancer	1.94e-05	0.000178	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FBXW7—esophageal cancer	1.94e-05	0.000177	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	1.93e-05	0.000176	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ELMO1—esophageal cancer	1.93e-05	0.000176	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.93e-05	0.000176	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS1—esophageal cancer	1.92e-05	0.000176	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ENO1—esophageal cancer	1.92e-05	0.000176	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.92e-05	0.000176	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HIST1H2BM—esophageal cancer	1.92e-05	0.000176	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—EGFR—esophageal cancer	1.91e-05	0.000175	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PDE4D—esophageal cancer	1.9e-05	0.000174	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PSME1—esophageal cancer	1.9e-05	0.000173	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PSME2—esophageal cancer	1.9e-05	0.000173	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—ERBB2—esophageal cancer	1.9e-05	0.000173	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CASP8—esophageal cancer	1.89e-05	0.000172	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKAP13—esophageal cancer	1.89e-05	0.000172	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CREBBP—esophageal cancer	1.88e-05	0.000172	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TPI1—esophageal cancer	1.86e-05	0.00017	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTO1—esophageal cancer	1.86e-05	0.00017	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HMGB1—esophageal cancer	1.85e-05	0.000169	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.83e-05	0.000168	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GNG7—esophageal cancer	1.81e-05	0.000165	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ELMO1—esophageal cancer	1.8e-05	0.000165	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALDOB—esophageal cancer	1.78e-05	0.000163	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TPI1—esophageal cancer	1.76e-05	0.000161	CbGpPWpGaD
Mesalazine—PTGS2—Disease—GSTO1—esophageal cancer	1.76e-05	0.000161	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIST1H2BM—esophageal cancer	1.74e-05	0.000159	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—SMAD4—esophageal cancer	1.73e-05	0.000159	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—EGFR—esophageal cancer	1.73e-05	0.000158	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PDE4D—esophageal cancer	1.72e-05	0.000158	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GAPDH—esophageal cancer	1.71e-05	0.000157	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CASP8—esophageal cancer	1.71e-05	0.000156	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ADH1B—esophageal cancer	1.7e-05	0.000156	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CREBBP—esophageal cancer	1.7e-05	0.000156	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CRABP1—esophageal cancer	1.7e-05	0.000155	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—XIAP—esophageal cancer	1.7e-05	0.000155	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ABL1—esophageal cancer	1.69e-05	0.000155	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—PIK3CA—esophageal cancer	1.69e-05	0.000154	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ALDOB—esophageal cancer	1.69e-05	0.000154	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—PIK3CA—esophageal cancer	1.66e-05	0.000152	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.66e-05	0.000151	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.65e-05	0.000151	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GNG7—esophageal cancer	1.64e-05	0.00015	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP1B1—esophageal cancer	1.64e-05	0.00015	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMP—esophageal cancer	1.63e-05	0.000149	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIST1H2BM—esophageal cancer	1.62e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS2—Disease—GAPDH—esophageal cancer	1.62e-05	0.000148	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—BCL2—esophageal cancer	1.62e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GNG7—esophageal cancer	1.61e-05	0.000148	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CTNNA1—esophageal cancer	1.6e-05	0.000147	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.6e-05	0.000146	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFBR2—esophageal cancer	1.6e-05	0.000146	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL2—esophageal cancer	1.59e-05	0.000146	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP26A1—esophageal cancer	1.58e-05	0.000145	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—ERBB2—esophageal cancer	1.57e-05	0.000144	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.56e-05	0.000143	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALOX15—esophageal cancer	1.54e-05	0.000141	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EP300—esophageal cancer	1.54e-05	0.000141	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP19A1—esophageal cancer	1.54e-05	0.000141	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—XIAP—esophageal cancer	1.54e-05	0.000141	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ABL1—esophageal cancer	1.53e-05	0.00014	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—PIK3CA—esophageal cancer	1.53e-05	0.00014	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALDH2—esophageal cancer	1.51e-05	0.000138	CbGpPWpGaD
Mesalazine—CHUK—Disease—SMAD4—esophageal cancer	1.51e-05	0.000138	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—ERBB2—esophageal cancer	1.51e-05	0.000138	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—PIK3CA—esophageal cancer	1.5e-05	0.000138	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PSME2—esophageal cancer	1.49e-05	0.000136	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PSME1—esophageal cancer	1.49e-05	0.000136	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ANXA1—esophageal cancer	1.48e-05	0.000136	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TPI1—esophageal cancer	1.47e-05	0.000135	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTO1—esophageal cancer	1.47e-05	0.000135	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—BCL2—esophageal cancer	1.47e-05	0.000134	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—CREBBP—esophageal cancer	1.46e-05	0.000133	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNA1—esophageal cancer	1.45e-05	0.000133	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL2—esophageal cancer	1.45e-05	0.000132	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SST—esophageal cancer	1.44e-05	0.000132	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTT1—esophageal cancer	1.44e-05	0.000132	CbGpPWpGaD
Mesalazine—PTGS2—Disease—XIAP—esophageal cancer	1.43e-05	0.000131	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—MYC—esophageal cancer	1.43e-05	0.000131	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ERBB2—esophageal cancer	1.43e-05	0.00013	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP2A6—esophageal cancer	1.42e-05	0.00013	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.42e-05	0.00013	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALDOB—esophageal cancer	1.41e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOTCH3—esophageal cancer	1.4e-05	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GHRL—esophageal cancer	1.4e-05	0.000128	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—HMOX1—esophageal cancer	1.4e-05	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FBXW7—esophageal cancer	1.38e-05	0.000126	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.38e-05	0.000126	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—ERBB2—esophageal cancer	1.37e-05	0.000125	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GAPDH—esophageal cancer	1.36e-05	0.000124	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.36e-05	0.000124	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PSME2—esophageal cancer	1.35e-05	0.000123	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PSME1—esophageal cancer	1.35e-05	0.000123	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ENO1—esophageal cancer	1.35e-05	0.000123	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ABCB1—esophageal cancer	1.35e-05	0.000123	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CRABP1—esophageal cancer	1.35e-05	0.000123	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CDKN1A—esophageal cancer	1.34e-05	0.000123	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ANXA1—esophageal cancer	1.34e-05	0.000123	CbGpPWpGaD
Mesalazine—PTGS2—Disease—B2M—esophageal cancer	1.33e-05	0.000122	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PSME2—esophageal cancer	1.33e-05	0.000122	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PSME1—esophageal cancer	1.33e-05	0.000122	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EGFR—esophageal cancer	1.31e-05	0.00012	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.31e-05	0.00012	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SST—esophageal cancer	1.31e-05	0.00012	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—NOS3—esophageal cancer	1.3e-05	0.000119	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDKN1A—esophageal cancer	1.29e-05	0.000118	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GNG7—esophageal cancer	1.28e-05	0.000117	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TLR4—esophageal cancer	1.28e-05	0.000117	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EP300—esophageal cancer	1.28e-05	0.000117	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ENO1—esophageal cancer	1.28e-05	0.000117	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—NOTCH1—esophageal cancer	1.28e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH3—esophageal cancer	1.27e-05	0.000116	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GHRL—esophageal cancer	1.27e-05	0.000116	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOTCH2—esophageal cancer	1.26e-05	0.000115	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PSME2—esophageal cancer	1.26e-05	0.000115	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PSME1—esophageal cancer	1.26e-05	0.000115	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FBXW7—esophageal cancer	1.25e-05	0.000115	CbGpPWpGaD
Mesalazine—CHUK—Disease—HIF1A—esophageal cancer	1.24e-05	0.000113	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CDKN1A—esophageal cancer	1.22e-05	0.000111	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CALR—esophageal cancer	1.21e-05	0.000111	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALDH2—esophageal cancer	1.2e-05	0.00011	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—esophageal cancer	1.19e-05	0.000109	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDKN1A—esophageal cancer	1.17e-05	0.000107	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FBXW7—esophageal cancer	1.17e-05	0.000107	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TLR4—esophageal cancer	1.16e-05	0.000106	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.16e-05	0.000106	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EP300—esophageal cancer	1.16e-05	0.000106	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—CREBBP—esophageal cancer	1.16e-05	0.000106	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP1B1—esophageal cancer	1.15e-05	0.000105	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH2—esophageal cancer	1.14e-05	0.000104	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTT1—esophageal cancer	1.14e-05	0.000104	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP2A6—esophageal cancer	1.13e-05	0.000103	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.12e-05	0.000103	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS2—esophageal cancer	1.12e-05	0.000103	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFBR2—esophageal cancer	1.12e-05	0.000102	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOTCH1—esophageal cancer	1.11e-05	0.000102	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CASP8—esophageal cancer	1.1e-05	0.0001	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CREBBP—esophageal cancer	1.09e-05	0.0001	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—esophageal cancer	1.09e-05	9.97e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP19A1—esophageal cancer	1.08e-05	9.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ENO1—esophageal cancer	1.07e-05	9.79e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTGS1—esophageal cancer	1.07e-05	9.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SMAD4—esophageal cancer	1.06e-05	9.68e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PSME1—esophageal cancer	1.05e-05	9.65e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PSME2—esophageal cancer	1.05e-05	9.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—esophageal cancer	1.05e-05	9.57e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.02e-05	9.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFBR2—esophageal cancer	1.01e-05	9.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CREBBP—esophageal cancer	1.01e-05	9.23e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CASP8—esophageal cancer	9.96e-06	9.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CREBBP—esophageal cancer	9.92e-06	9.07e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—EP300—esophageal cancer	9.91e-06	9.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—esophageal cancer	9.88e-06	9.04e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HMOX1—esophageal cancer	9.84e-06	9e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.65e-06	8.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SMAD4—esophageal cancer	9.59e-06	8.77e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—esophageal cancer	9.49e-06	8.68e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—esophageal cancer	9.46e-06	8.65e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFBR2—esophageal cancer	9.45e-06	8.65e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ABCB1—esophageal cancer	9.44e-06	8.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—BCL2—esophageal cancer	9.43e-06	8.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—esophageal cancer	9.16e-06	8.38e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP1B1—esophageal cancer	9.1e-06	8.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—esophageal cancer	9.08e-06	8.31e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS3—esophageal cancer	9.04e-06	8.27e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CREBBP—esophageal cancer	9.01e-06	8.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SMAD4—esophageal cancer	8.95e-06	8.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HIF1A—esophageal cancer	8.66e-06	7.92e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—esophageal cancer	8.58e-06	7.84e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP19A1—esophageal cancer	8.56e-06	7.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2—esophageal cancer	8.55e-06	7.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—esophageal cancer	8.46e-06	7.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—esophageal cancer	8.3e-06	7.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KDR—esophageal cancer	8.28e-06	7.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—esophageal cancer	8.27e-06	7.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—esophageal cancer	8.24e-06	7.53e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NOS3—esophageal cancer	8.06e-06	7.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIF1A—esophageal cancer	7.85e-06	7.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1A—esophageal cancer	7.83e-06	7.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HMOX1—esophageal cancer	7.81e-06	7.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOTCH1—esophageal cancer	7.8e-06	7.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.66e-06	7.01e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KDR—esophageal cancer	7.51e-06	6.87e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCB1—esophageal cancer	7.49e-06	6.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EP300—esophageal cancer	7.45e-06	6.81e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—esophageal cancer	7.38e-06	6.75e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—esophageal cancer	7.33e-06	6.7e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIF1A—esophageal cancer	7.32e-06	6.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1A—esophageal cancer	7.23e-06	6.61e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.14e-06	6.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1A—esophageal cancer	7.1e-06	6.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH1—esophageal cancer	7.07e-06	6.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CREBBP—esophageal cancer	7.07e-06	6.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EP300—esophageal cancer	6.88e-06	6.29e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—esophageal cancer	6.87e-06	6.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EP300—esophageal cancer	6.75e-06	6.18e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS2—esophageal cancer	6.66e-06	6.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOTCH1—esophageal cancer	6.6e-06	6.03e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CREBBP—esophageal cancer	6.41e-06	5.86e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—esophageal cancer	6.35e-06	5.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOS3—esophageal cancer	6.33e-06	5.79e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CREBBP—esophageal cancer	6.31e-06	5.77e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—EP300—esophageal cancer	6.13e-06	5.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—esophageal cancer	5.99e-06	5.48e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CREBBP—esophageal cancer	5.98e-06	5.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—esophageal cancer	5.92e-06	5.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—esophageal cancer	5.86e-06	5.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—esophageal cancer	5.76e-06	5.26e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOS3—esophageal cancer	5.74e-06	5.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.67e-06	5.18e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NOS3—esophageal cancer	5.65e-06	5.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—esophageal cancer	5.51e-06	5.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—esophageal cancer	5.37e-06	4.91e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS3—esophageal cancer	5.35e-06	4.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—esophageal cancer	5.23e-06	4.78e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—esophageal cancer	5.17e-06	4.73e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—esophageal cancer	5.09e-06	4.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1A—esophageal cancer	5.06e-06	4.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CREBBP—esophageal cancer	5.01e-06	4.58e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—esophageal cancer	5.01e-06	4.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—esophageal cancer	5e-06	4.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EP300—esophageal cancer	4.82e-06	4.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—esophageal cancer	4.74e-06	4.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1A—esophageal cancer	4.59e-06	4.2e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—esophageal cancer	4.54e-06	4.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NOS3—esophageal cancer	4.48e-06	4.1e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EP300—esophageal cancer	4.37e-06	3.99e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—EP300—esophageal cancer	4.3e-06	3.93e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1A—esophageal cancer	4.28e-06	3.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—esophageal cancer	4.2e-06	3.84e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—esophageal cancer	4.1e-06	3.75e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EP300—esophageal cancer	4.07e-06	3.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—esophageal cancer	3.8e-06	3.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—esophageal cancer	3.72e-06	3.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—esophageal cancer	3.56e-06	3.26e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—esophageal cancer	3.55e-06	3.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—esophageal cancer	3.47e-06	3.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—esophageal cancer	3.45e-06	3.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—EP300—esophageal cancer	3.41e-06	3.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—esophageal cancer	3.23e-06	2.95e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—esophageal cancer	3.18e-06	2.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—esophageal cancer	3.12e-06	2.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—esophageal cancer	3.01e-06	2.76e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—esophageal cancer	2.52e-06	2.31e-05	CbGpPWpGaD
